3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
37
Neoplasms
30
Colorectal Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Neoplasm Metastasis
5
Rectal Neoplasms
3
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Glioma
3
Colonic Neoplasms
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Oligodendroglioma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Astrocytoma
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Skin Neoplasms
1
Interventions
Fluorouracil
2
Capecitabine
2
tremelimumab
1
trametinib
1
temoporfin
1
durvalumab
1
dehydroftorafur
1
Sorafenib
1
Self Expandable Metallic Stents
1
Radiosurgery
1
Platinum
1
Oxaliplatin
1
N-Ac-CHAVC-NH2
1
Leucovorin
1
Hydroxychloroquine
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Cisplatin
1
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Klatskin Tumor
×
trametinib
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts